40 results about "HDL - High density lipoprotein" patented technology

Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

The present invention provides a non-naturally occurring High-Density Lipoprotein-like peptide-phospholipid scaffold (“HPPS”) nanoparticle. More particularly, the invention provides a non-naturally occurring peptide-lipid nanoscaffold comprising: (a) at least one phospholipid; (b) at least one unsaturated lipid, preferably an unsaturated sterol ester, further preferably an unsaturated cholesterol ester, further preferably cholsteryl oleate; and (c) at least one peptide, the peptide comprising an amino acid sequence capable of forming at least one amphipathic a-helix; wherein the components a), b) and c) associate to form the peptide-phospholipid nanoscaffold. In embodiments of the present invention, a cell surface receptor ligand is incorporated into the HPPS. In one embodiment, the cell surface receptor ligand is covalently bonded to the peptide scaffold of the HPPS nanoparticles. In other embodiments, a cell surface receptor ligand is coupled to a lipid anchor and is displayed on the surface of the HPPS nanoparticles by incorporation of the lipid anchor into the phospholipids monolayer of the HPPS nanoparticle. The present invention also provides pharmaceutical formulations comprising HPPS nanoparticles and methods of making the HPPS nanoparticles.

PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

The present invention relates to compositions for use in raising or lowering the level of LIPG polypeptide in a patient. Embodiments of the composition include compositions comprising: an anti-sense nucleic acid; a neutralizing antibody; an intracellular binding protein; an inhibitor which inhibits the enzymatic activity of LIPG polypeptide; an inhibitor which inhibits the expression of LIPG gene; a ribozyme; an LIPG polypeptide; an enhancer which increases the enzymatic activity of LIPG polypeptide; or an enhancer which increases the expression of LIPG gene. The invention relates also to methods for using the above compositions.In addition, the invention relates to a method for diagnosing a predisposition to lower cholesterol, a method for determining whether a test compound can inhibit the enzymatic reaction between LIPG polypeptide and HDL cholesterol, and methods for determining whether a test compound can enhance the enzymatic reaction between LIPG polypeptide and LDL or VLDL cholesterol.

A method for quantitating a specific component in lipoproteins contained in a biological sample, for example, HDL (high-density lipoprotein), LDL (low-density lipoprotein) or VLDL (very low-density lipoprotein) by using a commonly employed automatic analyzer without centrifuging or making the reaction liquor cloudy due to complexes or aggregates. Namely, a controlling means, whereby an enzyme reaction can be carried out exclusively for the target component, is introduced into a method for enzymatically assaying a component in a specific lipoprotein fraction in the serum, thereby specifically assaying the component.

This invention provides novel assays for the detection of dysfunctional HDL. The assays are good diagnostics and / or prognostics for atherosclerosis or other pathologies characterized by an inflammatory response. In certain embodiments the methods involve measurements of heme-related HDL-associated proteins (e.g., haptoglobin, hemopexin, etc.), and / or measurements of the relative distribution of HDL-associated proteins between HDL and the non-lipoprotein fractions of plasma / serum, and / or measurements of the ability of pro-inflammatory HDL to consume nitric oxide, and / or measurement of the ability of HDL to inhibit LDL aggregation.

A method for determination of sdLDL-C, which comprises the steps of: (i) in a reaction solution containing a surfactant which preferentially inhibits the reaction of sdLDL-C with enzymes for cholesterol measurement such as cholesterol ester hydrolase, allowing the enzymes for cholesterol measurement to act on a sample to eliminate HDL-C, VLDL-C, CM-C and LgLDL-C in the sample; (ii) adding a reagent which causes the reaction of sdLDL-C remaining in the reaction solution after the above step (i) to form hydrogen peroxide or reduced coenzyme, and measuring the formed hydrogen peroxide or reduced coenzyme; and (iii) determining the sdLDL-C concentration in the sample from the measurement value in (ii) and a previously prepared calibration curve.

This invention provides novel assays for the detection of dysfunctional HDL. The assays are good diagnostics and / or prognostics for atherosclerosis or other pathologies characterized by an inflammatory response. In certain embodiments the methods involve measurements of heme-related HDL-associated proteins (e.g., haptoglobin, hemopexin, etc.), and / or measurements of the relative distribution of HDL-associated proteins between HDL and the non-lipoprotein fractions of plasma / serum, and / or measurements of the ability of pro-inflammatory HDL to consume nitric oxide, and / or measurement of the ability of HDL to inhibit LDL aggregation.

The invention provides a method for extracting high-density lipoprotein (HDL) and separating and purifying high-purity apolipoprotein apoA-I from normal human plasma. The method comprises the following steps: (1) regulating plasma to be of different densities by utilizing neutral salt, and eliminating impure protein by utilizing a sequential gradient density supercentrifugation method, so as to obtain a high-purity HDL component; (2) carrying out degreasing on the obtained high-purity HDL component in a flowingly adding manner by utilizing a certain proportion of alcohol ether solvents under a low-temperature freezing state, so as to obtain degreased apoHDL precipitates; (3) redissolving the apoHDL precipitates by utilizing a TBS buffer liquid system containing 1-8M urea, filtering, carrying out separation and purification by molecular sieve chromatography of filtrate and anion exchange chromatography in sequence to obtain a high-purity apoA-I solution. According to the method, albumin components which are very difficult to remove can be separated from the HDL; the apoA-I prepared by utilizing the method has very high purity and activity, the purity can reach above 98%, and the apoA-I can generate clear precipitin reaction with antiserum after being diluted by 64 times; the method is safe and convenient to operate, is short in extraction period and is suitable for industrial production.

The invention discloses an amphipathic low-density lipoprotein adsorbent and a preparation method thereof. A skeleton of the adsorbent is a carrier, taurine is immobilized on the surface of the carrier, and deoxycholic acid is coupled on the taurine. According to the amphipathic low-density lipoprotein adsorbent disclosed by the invention, by using electrostatic interaction of a sulfo group, LDL (low-density lipoprotein) can be effectively adsorbed and removed; condensed deoxycholic acid is further utilized, adsorption to beneficial element HDL (high density lipoprotein) is reduced through the hydrophobic and steric hindrance effects of the naphthene structure, total cholesterol (TC) and triglyceride(TG) can be removed, and the selective removal ability of the adsorbent is improved. The amphipathic low-density lipoprotein adsorbent disclosed by the invention carries the hydrophilic sulfonic group and hydrophobic deoxycholic acid, can simulate hydrophilic and hydrophobic structures of phospholipid molecules, has better blood compatibility with cells, and is suitable for whole blood perfusion. By adjusting the ratio of the hydrophilic and hydrophobic groups, the adsorbent with high blood compatibility and capable of specifically adsorbing LDL (low-density lipoprotein) can be obtained.

This invention provides novel assays that are prognostic and / or diagnostic for atherosclerosis or risk of atherosclerosis. It was discovered that high density lipoprotein (HDL) or components thereof can prevent the oxidation of lipids (e.g., lipids present in LDLs) and can also repair (reduce) already oxidized lipids and thereby reduce the inflammatory response associated with and characteristic of atherosclerotic plaque formation. Moreover it was a discovery of this invention that individuals vary in the ability of their HDL to afford such protection. Thus an assay of HDL protective and / or repair activity provides a highly effective assay for risk of atherosclerosis and its associated pathologies and such assays are provided herein.

The invention relates to a human high density lipoprotein and product, preparation process and use thereof, which comprises producing human plasma albumin and gamma globulin by employing low-temperature ethanol method, using discarded FIV-1 deposition as raw material, extracting HDL from FIV-1 through separation and purification steps. The prepared human high density lipoprotein and product can be applied for the preparation of medicament for treating multiple organ disturbance syndrome (MODS) and cardiovascular diseases such as atherosclerosis (AS).

The invention discloses an entecavir high-density lipoprotein enveloping preparation, and a preparation method and a use thereof. The entecavir high-density lipoprotein enveloping preparation contains entecavir, phospholipid, cholesterol and ApoAl in the weight ratio of 5: 7: 3: (5-20).

The invention discloses a method for chemiluminiscence imaging immunoassay method for simultaneously measuring oxidized lipoproteins (a) and low-density oxidized lipoproteins of human serum. According to an analysis system, a multi-component immunosensor modified by silanization is used as a solid-phase carrier; a solid-phase antibody is prepared by covering the carrier with a capturing antibody; a sample to be measured or a standard series solution is added into the solid-phase antibody; after the solid-phase antibody and the sample to be measured or the standard series solution fully react, an antibody labeled with horse radish peroxidase is added to form a sandwich immune compound; finally a chemiluminescence substrate, namely luminal-hydrogen peroxide, is added for reaction; the luminous intensity is detected through a high-resolution charge coupler, so that the oxidized lipoproteins (a) and the low-density oxidized lipoproteins of the human serum can be measured simultaneously, and the immune reaction condition, the enzyme conjugate dilution degree, the detection time and the like are optimized; furthermore, the indexes such as linear range, precision, accuracy and detection limit of the method are checked. The analysis method has the advantages of simplicity in operation, high sensitivity, narrow linear range, high stability and the like and has a certain clinical application value.

A method including introducing into a blood stream a delipidated high density lipoprotein (HDL) and a bioactive agent. A composition including a delipidated high density lipoprotein (HDL) and an auxiliary agent in a form suitable for delivery into a blood vessel. A composition including Apo A1 comprising a hydrophobic ligand suitable to interact with cell surface binding sites. A composition including Apo A1 and an agent selected to one of increase the ATP-binding cassette protein 1 (ABCA1) transporter expression in macrophages and protect ABCA1 from thiol-mediated degradation.

A method of assaying cholesterol of high-density lipoprotein in an analyte, comprising reacting an analyte with (i) cholesterol ester hydrolase and cholesterol oxidase, or (ii) cholesterol ester hydrolase, oxidized coenzyme and cholesterol dehydrogenase, in an aqueous medium containing at least one substance selected from the group consisting of an alkylamine polyoxyethylene polyoxypropylene condensate, a polyoxyethylenealkylamine sulfate, a polyoxyethylenebenzyl-alkyl quaternary ammonium salt, a polyoxyethylene acid amide, an alkylamine oxide and an alkylpropylenediamine derivative to thereby produce hydrogen peroxide or reduced coenzyme, and measuring the produced hydrogen peroxide or reduced coenzyme.

A method for determination of sdLDL-C, which comprises the steps of: (i) in a reaction solution containing a surfactant which preferentially inhibits the reaction of sdLDL-C with enzymes for cholesterol measurement such as cholesterol ester hydrolase, allowing the enzymes for cholesterol measurement to act on a sample to eliminate HDL-C, VLDL-C, CM-C and LgLDL-C in the sample; (ii) adding a reagent which causes the reaction of sdLDL-C remaining in the reaction solution after the above step (i) to form hydrogen peroxide or reduced coenzyme, and measuring the formed hydrogen peroxide or reduced coenzyme; and (iii) determining the sdLDL-C concentration in the sample from the measurement value in (ii) and a previously prepared calibration curve.

The present invention provides a method, a reagent and a kit for the simple and accurate measurement of HDL cholesterol. The method for the measurement of cholesterol in high-density lipoprotein in a sample comprises reacting the sample with i) cholesterol esterase and cholesterol oxidase or ii) cholesterol esterase, oxidized coenzyme and cholesterol dehydrogenase in an aqueous medium comprising a specific nitrogen-containing surfactant having the structure of amine or ammonium salt and a polyanion, and measuring the formed hydrogen peroxide or reduced coenzyme.

The invention provides a quantum dot low-density lipoprotein nano-composite probe as well as a preparation method and application. The quantum dot low-density lipoprotein nano-composite probe is prepared from low-density lipoprotein, cationic polyelectrolyte and water-soluble quantum dots; the low-density lipoprotein is the core; and the water-soluble quantum dots are coupled to the low-density lipoprotein through the cationic polyelectrolyte. The low-density lipoprotein and the water-soluble quantum dots are assembled by adopting an electrostatic grafting method to form the fluorescent probe,and the probe has the very strong chemical stability and biocompatibility, and can provide the excellent spectral resolution.

This invention provides novel assays for the detection of dysfunctional HDL. The assays are good diagnostics and / or prognostics for atherosclerosis or other pathologies characterized by an inflammatory response. In certain embodiments the methods involve measurements of heme-related HDL-associated proteins (e.g., haptoglobin, hemopexin, etc.), and / or measurements of the relative distribution of HDL-associated proteins between HDL and the non-lipoprotein fractions of plasma / serum, and / or measurements of the ability of pro-inflammatory HDL to consume nitric oxide, and / or measurement of the ability of HDL to inhibit LDL aggregation.

The invention relates to a test reagent of cholesterol in high-density lipoprotein. The test reagent comprises a test reagent main body, wherein the test reagent further comprises a stabilizer according to parts by weight, and the weight ratio of the stabilizer to the test reagent main body is 50:1; and the stabilizer comprises 10-20 parts of alkylolamides, 4-8 parts of sodium salicylate, 3-6 parts of anti-interference substance, and 30-50 parts of chitosan. The stability of the test reagent main body is greatly enhanced, thereby prolonging the storage time of the test reagent main body. Because the thickness of the chitosan is large, and the degree of crosslinking of the chitosan is large, so that a dense net structure is formed easily.

An application of the high-density lipoprotein (HDL) and its apolipoprotein in preparing the liquid injection or freeze-dried powder injection for treating the envelope virus diseases including influenza, fowl influenza infection, SARS, AIDS, hepatitis B and C, etc is disclosed.

The present invention inter alia relates to methods and uses involving the determination of lipid / lipid concentration ratios in order to diagnose, predict, prevent and / or treat atherosclerosis or cardiovascular disease (CVD) and its complications including, e.g., acute myocardial infarction. The methods include analyzing lipid concentrations and resulting lipid / lipid concentration ratios of a non-high density lipoprotein samples from patients and comparing them to a control.

The invention relates to novel molecules that can modulate one of the mechanisms leading to the massive deposition of cholesterol in the cardiomyocytes and / or in the smooth muscle cells of the vascular wall, during acute myocardial infarction or other clinical situations involving ischaemia. The invention also shows that the blockage of LRP1 by means of certain agents, including a recombinant expression vector, an RNAi, an antibody, a siRNA etc., prevents the overaccumulation of esterified cholesterol in the cardiomyocytes and / or in the smooth muscle cells of the vascular wall exposed to ischaemia. The invention also relates to the use of said molecules in the treatment and / or prevention of the changes in the metabolism of calcium and cardiac remodeling associated with ischaemia.

A new measurement method by which LDL cholesterol can be measured readily and precisely is provided. The measurement method is for measuring LDL cholesterol in a sample.

Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

Disclosed is the provision of a method for quantifying HDL3 in a test sample without requiring a laborious operation. The method for quantifying cholesterol in high-density lipoprotein 3 comprises allowing a surfactant(s) which specifically react(s) with a high-density lipoprotein 3 to react with a test sample and quantifying cholesterol, and the surfactant(s) is(are) at least one selected from the group consisting of polyoxyethylene polycyclic phenyl ether and polyoxyethylene styrenated phenyl ether.

The invention discloses a determination reagent of cholesterols in serum high density lipoprotein. The reagent comprises a proper amount of an antiseptic, a stabilizer, a toner, a high affinity enzyme compound, a surfactant and bovine serum albumin, and the high affinity enzyme compound is prepared through the following steps: 1, carrying out enzyme activation: selecting an enzyme, pre-culturing the enzyme, carrying out activation culture on the enzyme, and carrying out a dehydration reaction; and 2, preparing the high affinity enzyme compound: selecting the compound, and carrying out a hybrid reaction. The reagent can be used to detect the cholesterols on a fully-automatic biochemical analyzer with various models without sample centrifuge, precipitation or other complicated operations, so the detection workload is greatly reduced, the detection time is shortened, and the detection cost is reduced; and the reagent has the advantages of good specificity, high sensitivity and high detection accuracy, and compared with a detection result of a nationally recommended Friedewald formula, the result of the reagent shows that the correlation reaches 0.997 or above.

A method that enables quantification of cholesterol in high-density lipoprotein 3 (HDL3) in a test sample without requiring a laborious operation is disclosed. The method for quantifying cholesterol in HDL3 comprises: Step 1 wherein phospholipase and / or sphingomyelinase is / are allowed to act on a test sample to transfer cholesterol to the outside of the reaction system; and Step 2 wherein cholesterol remaining in the reaction system is quantified. The method enables specific quantification of HDL3 cholesterol in a test sample using an automatic analyzer without requirement of a laborious operation such as ultracentrifugation or pretreatment. Further, quantification of the HDL2 cholesterol level can also be carried out by subtracting the HDL3 cholesterol level from the total HDL cholesterol level obtained by a conventional method for quantifying the total HDL cholesterol in a test sample.